Evolution of HER2-low expression from primary to recurrent breast cancerFederica Miglietta, Maria Vittoria Dieci, Gaia Griguolo et al.|npj Breast Cancer|2021Cited by 226
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatmentFederica Miglietta, Maria Vittoria Dieci, Gaia Griguolo et al.|npj Breast Cancer|2022Cited by 100
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapyMaria Vittoria Dieci, PierFranco Conte, Davide Massa et al.|European Journal of Cancer|2020Cited by 74
The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic StrategiesGiovanni Zarrilli, Matteo Fassan, Gianluca Businello et al.|International Journal of Molecular Sciences|2020Cited by 36
Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive casesElisabetta Di Liso, Valentina Guarneri, Michele Bottosso et al.|ESMO Open|2020Cited by 33